USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Regeneron Pharmaceuticals Records Growth in Q3 Revenue and Net Income

The Motley Fool +1 · ·by G4L

REGN Regeneron Pharmaceuticals Inc
$955.47 +0.45%
View chart & analysis →
  1. 1Regeneron's total revenue growth rate recorded 36% compared to Q3 2025.
  2. 2Regeneron achieved a 70% growth rate in non-GAAP earnings per share compared to Q3 2025.
  3. 3Regeneron Pharmaceuticals expanded its partnership with Sanofi.

So what's the key point?

Regeneron Pharmaceuticals' revenue increased by 36% and net income also grew. The company expanded its partnership with Sanofi.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Regeneron trades at 20x earnings with $16 billion in net cash The Motley Fool +1 · 1h agoAstraZeneca Cost Cutting, Alnylam Shares Plunge, Regeneron Earnings Beat BioPharma Dive · Nov 2Regeneron Beats Q3 Revenue and Profit Estimates, Shares Rise 4% Investing.com +1 · Oct 30
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news